#Canada #Vancouver #Optimi Health #Nasdaq Offering #Psychedelic Drugs

Optimi Health Announces Successful $15 Million Public Offering

Optimi Health Corp. has made headlines with its recent announcement regarding the pricing of a substantial public offering that has garnered significant investor interest. The company, which operates on the cutting edge of the pharmaceutical sector, specializing in the manufacturing and distribution of psychedelic drug products, is moving forward with an initial public offering priced at $6.25 per share. This strategic move comes as the company elevates its profile by uplisting its common shares to the Nasdaq Capital Market under the ticker symbol 'OPTH.'

On May 20, 2026, Optimi reported that it would be offering 2.4 million common shares, with the underwriters having the option to purchase an additional 360,000 shares. This offering is expected to raise gross proceeds of approximately $15 million, which will be allocated for scaling production and expanding market reach, particularly in the United States. The closing of the offering is anticipated around May 21, subject to satisfactory closing conditions.

Future Plans and Market Expansion

The funds secured from this offering are set to bolster Optimi's ability to enhance its operations, ramp up production capabilities, and facilitate market expansion efforts. The company's management has indicated that the net proceeds will support its goal of increasing sales and managing operating expenses. Key to this strategy is expanding into new markets, including the potentially lucrative U.S. market.

Optimi Health is not just any pharmaceutical company; it holds the prestigious title of being a Health Canada-licensed manufacturer, producing Good Manufacturing Practice (GMP)-grade psychedelic products. Optimistic about the future, CEO of Optimi Health expressed confidence in the company's innovative products aimed at addressing mental health challenges. The company's validated MDMA and botanical psilocybin products have already started making their way into regulated clinical programs, showing the increasing acceptance and demand for psychedelics in therapeutic settings.

In conjunction with this major offering, Optimi has also taken steps to consolidate its share structure. As previously announced, a consolidation of outstanding shares occurred, with every thirty pre-consolidation shares replaced by one post-consolidation share, effective May 19, 2026. The company expects that after this consolidation and the anticipated offering, it will have around 3.2 million common shares issued and outstanding.

Regulatory Compliance and Investor Information

To maintain transparency with investors, Optimi Health has been diligent in aligning its operations with regulatory expectations. The offering complies with Securities and Exchange Commission (SEC) regulations as outlined in the registration statement on Form F-1, which became effective just a day prior to the offering. Investors are encouraged to review comprehensive documents provided by the company, including the offering prospectus, to obtain insights into their investment.

In addition to regulatory adherence, the company is committed to maintaining ongoing communications with its shareholders, ensuring they are informed of developments related to the offering and the business's trajectory. Optimi Health's robust response to investor inquiries highlights its dedication to building investor confidence as it transitions to a prominent market player.

Conclusion

As Optimi Health embarks on this exciting chapter, its strategic moves underscore a commitment to not only advancing in the pharmaceutical landscape but also significantly contributing to the evolving discussions around mental health and the therapeutic potential of psychedelics. Staying attuned to market dynamics and aligning with regulatory frameworks will be essential as the company progresses. This public offering, coupled with the company's uplisting to Nasdaq, is poised to elevate Optimi Health's position significantly within the industry, potentially changing the landscape of mental health therapy in the process.